Corvus Pharmaceuticals, Inc. , a company developing cancer treatment drugs, opened at $15 a share Wednesday in its debut on the Nasdaq. The company had priced its offering at $15 Tuesday night at the low-end of its $15 to $17 range. Corvus Pharmaceuticals sold 4.7 million shares to raise about $70.5 million. Cowen & Co., and Credit Suisse Securities were the lead underwriters of the offering. Shares of Corvus were trading at $14.90 in early morning trade.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
From:: Stock Market News